Company intelligence / Profile preview

CannScience Innovations

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

CannScience obtained regulatory approval in January 2016 to conduct cannabis research in Canada through a collaboration with the University Health Network. The company intended to develop intellectual property related to extraction processes, standardized product formulations, and new non-smoked delivery methods, with plans to conduct preclinical and clinical testing for regulatory approval in Canada and internationally.

Therapeutic areas: OncologyGastroenterologyNeurologyPsychiatry
Modalities: Small molecule (cannabinoid-based formulations)Device
Industry: Biotech

Partnerships

University Health Network (strategic collaboration for research)Generex Biotechnology Corporation (RapidMist technology license)

Beyond the preview

Go deeper on CannScience Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CannScience Innovations.

Explore the full profile